A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Sponsor: Incyte Corporation
This PHASE2 trial investigates MPN (Myeloproliferative Neoplasms) and is currently completed. Incyte Corporation leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Jun 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .